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Background: Diabetes and Nephrotic syndrome (NS) promote plaque-related gingivitis and yeast-like fungal infections.
The study assesses the impact of Candida spp. and general disease- or treatment-related factors on plaque-related
gingivitis severity in children and adolescents with Nephrotic syndrome /diabetes.
Methods: Body mass index (BMI), BMI standard deviation score, and oral cavity (Plaque Index – PLI, Gingival
Index – GI, mucosa status, presence and Candida enzymatic activity) were assessed in 96 patients (32 with NS:
30- immunosuppressive treatment, 35 - type 1 diabetes, and 29 generally healthy), aged; 3–18 years. Laboratory
included cholesterol and triglyceride measurements; in diabetic subjects– glycated haemoglobin, in NS: total
protein, albumin, creatinine, haemoglobin, haematocrit, white cell count, urinary protein excretion. Medical
records supplied information on disease duration and treatment. A statistical analysis was performed; Kendall Tau
coefficient, chi-square test, t-test, and multiple regression analysis ( P < 0.05).
Results: Candida spp. often occurred in healthy patients, but oral candidiasis was found only in the NS and
diabetes groups (9.37% and 11.43%). Gingivitis occurred more frequently in patients with NS/diabetes. Gingivitis
severity was correlated with PLI, age, and yeast enzyme activity in NS – to with immunosuppressive treatment
with >1 drug, drug doses, treatment duration, lipid disorders, and BMI; in diabetes, with blood glucose and
glycated haemoglobin >8%.
Conclusion: Poor hygiene control is the main cause of gingivitis. Gingivitis severity is most likely related to age,
lipid disorders and increase in body mass. Candida spp., in uncompensated diabetes and in those using
immunosuppressive treatment, might intensify plaque-related gingivitis.
Keywords: Oral cavity, Immunosuppression, Nephrotic syndrome, Type 1 diabetes, Candida spp, Hydrolytic
enzyme activity, GingivitisBackground
Both diabetes and immunosuppressive treatment predis-
pose children to plaque-related gingivitis and oral yeast
infections [1-12]. Both diseases present a number of fac-
tors promoting bacterial and fungal infections. Reduced
salivary flow and modified salivary composition might
occur in uncompensated diabetes [13]. Neutrophil activ-
ity and cell-mediated immunity are impaired. Patients
with diabetes are even considered to present a modified* Correspondence: do-k@o2.pl
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article, unless otherwise stated.oral bacterial flora, which might promote fungal infections
[14,15]. An impaired cellular response is also related to
long-term immunosuppressive treatment in Nephrotic
syndrome. The syndrome (NS) is a clinical condition
with a proteinuria level exceeding the body’s compensating
abilities (protein loss over 50 mg/kg/day). Proteinuria re-
sults in hypo- and dysproteinaemia, hyperlipidaemia, and
modifications in immunoglobulin composition (including
decreased IgG levels), which additionally impair the body’s
immunity [16].
Candida spp. often colonises the oral cavity without
presenting any lesions. However, candidiasis symptoms
also occur in an impaired defence mechanism and fungus-ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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found in non-candidiasis related oral mucosal lesions
[20,21]. They may cause gingivitis, developing independ-
ently out of plaque, such as linear gingival erythema
(LGE) manifesting as gingival margin erythema. It may
also sometimes develop from the attached related gingiva,
and manifest as spontaneous bleeding [4,22].
Yeast-like fungi might also lead to periodontitis. Can-
dida albicans has been isolated from periodontal pockets
and root canals [23-25]. The production of inflammatory
cytokines is said to be more important in the presence of
C. albicans as a response to cellular wall lipopolysacchar-
ide activity, and thus increasing the severity of periodon-
titis [26,27]. Candida albicans has also been found to
facilitate the P. gingivalis’ invasion into epithelial cells and
fibroblasts [28].
Detection of yeast-like fungi does not prove their role
in lesion formation. It is crucial to determine their invasive
capacity, reflected in the activity of hydrolytic enzymes
produced by yeast-like fungi, including alpha–glucosidase
(E16) and β-N-acetylglucosaminidase (E18) [29-33]. E16
and E18 were proven to inhibit neutrophil migration to the
source of the infection [33]. Beta-N-acetylglucosaminidase
has also been found to induce filamentation, i.e. it exerts it
impact on the formation of ‘germ tubes’ [32]. An import-
ant activity of these enzymes at the lesion site might reflect
the pathogenic role of yeast-like fungi.
Children and teenagers with diabetes and with NS
undergoing immunosuppressive treatment are predisposed
to gingivitis. Candida spp. has often colonises the oral
cavity, and candidiasis occurs more frequently than in the
general healthy population. In the previous study, Candida
spp. was isolated in 45.4% of children with nephrotic syn-
drome undergoing immunosuppressive treatment, and in
14.8% of those with type 1 diabetes. Oral candidiasis was
diagnosed in 13.3% of patients with NS and in 11.1% of
those with uncompensated diabetes [4]. However, evenTable 1 Age and sex of patients qualified to the study and bi
syndrome or type 1 diabetes
Group Number of patients (girls/boys) Age in years
Control group 29 (10/19) 3-17.1 (11.52 ±
Nephrotic syndrome 32 (13/19) 3-18 (10.05 ±
Type 1 diabetes 35 (17/18) 6-17.9 (13.24 ±though yeast-like fungi might intensify the infection, their
impact on the condition of the gingiva in those diseases
has not been assessed.
The present study has assessed the impact of Candida
spp. and the general factors related to the disease or its
treatment in the severe plaque-related gingivitis in children
and adolescents with diabetes or Nephrotic syndrome.
Methods
The study was conducted using 96 subjects: 32 with NS,
35 with type 1 diabetes, and 29 that were generally healthy
(control group) (Table 1). The inclusion criteria were: age
from between 3 to 18 years and a written informed con-
sent of the child and/or their parent/guardian, as well as:
 In the NS group: no treatment with drugs other
than those used in the treatment of NS, no chronic
disease other than kidney disease
 In the diabetes group: no chronic disease other than
diabetes or drug therapy
 In the control group: no chronic disease or drug
therapy
The exclusion criteria included: tobacco smoking, ortho-
dontic appliances or dental prosthesis use, antifungal treat-
ments, and antibiotic therapy at the time of qualification
for the study and during the three previous weeks. The NS
and diabetes groups included patients referred to the
dentists by paediatricians and those who presented
themselves for a check up at a nephrology or diabetes
clinic. Patients presenting for the first time at the De-
partment of Paediatric Dentistry were qualified to par-
ticipate in the control group.
The Warsaw Medical University Committee for Ethics
approved the study. The study was prospective and in-
cluded a general medical and oral examination (clinicalochemical characteristics of children with nephrotic
range (mean ± SD) Biochemical parameter Mean ± SD
4.01 ) - -
4.8) Proteinuria (mg/kg/day) 73.2 ± 104.24
Albumin (g/dL) 3.54 ± 0.84
Total protein (g/dL) 6.4 ± 1.17
Haemoglobin (g%) 13.73 ± 1.46
Hematocrit (%) 41.74 ± 4.37
Leukocyte count (x103/mm3) 9.8 ± 3.16
Cholesterol (mg/dL) 262.29 ± 127.33
Triglycerides (mg/dL) 176.33 ± 165.23
2.64) Blood glucose level (mg/dL) 173.94 ± 70.3
HbA1c (%) 8.93 ± 2.16
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review. The oral examination was performed following
the general medical examination (clinical and sampling
for the scheduled laboratory tests) on the same or fol-
lowing day. Just prior to the clinical the obtained swabs
were sent for mycological testing. The dentists were only
aware of the patient’s disease (diabetes or Nephrotic syn-
drome). They did not know the general medical details
of the NS and diabetes patients, including the main dis-
ease course and treatment plan, neither of the occur-
rence of other diseases. The statistical analysis of the
obtained results was also performed.
General medical examination
BMI was calculated in kg/m2 for all clients, and adjusted
to their age and gender to provide a BMI standard devi-
ation score (SDS) [34].
NS group
Information on the NS patient treatment was obtained
from available medical records, including that on the ad-
ministered drugs with dosage and treatment duration.
Laboratory blood tests included total protein (reference
range 6–8 g/dL), albumin (reference range 3.7–5.6 g/dL),
creatinine, cholesterol, triglycerides, haemoglobin, haem-
atocrit (reference ranges, depending on age), and white
blood cell count, measured with standard laboratory
methods. A 24-hour urinary protein excretion was mea-
sured using turbidimetry.
Diabetes group
Information on diabetes duration was obtained from the
available medical records. Laboratory data, including mea-
surements of glycated haemoglobin – HbA1c (with D-10
high-performance liquid chromatography), blood glu-
cose levels (with a testing strip using a standard glucose
metre), cholesterol and triglycerides, using standard
laboratory methods, were collected. The criteria for
compensated diabetes were: HbA1c <7% – good, 7–8%
– average, and >8%– bad.
Oral assessment included the oral mucosa, general
hygiene level, and gingiva
Oral candidiasis was assessed according to the World
Health Organisation guidelines [35]. The oral hygiene
score was based on the Silness and Löe plaque index
(PLI). Plaque deposits were assessed in the cervical area
of six teeth: 16, 12, 24, 36, 32, 44 (55, 51, 63, 75, 71, 83
in deciduous teeth), according to the criteria: 0 – no
plaque, 1 – a film of plaque visible on probing the gingival
margin, 2 – visible accumulation of deposits, 3 – abun-
dance of soft matter within the gingival pocket [36]. The
index is the quotient of the sum of the values obtained
for all studied tooth surfaces (medial, distal, buccal, andlingual) and the number of examined areas. The gingival
score was based on the Silness and Löe Gingival Index
(GI). The gingival tissues were assessed around the same
teeth according to the following criteria:
0. No inflammation – healthy gingiva
1. Mild inflammation – slight change in colour and in
tissue structure; no bleeding on probing
2. Moderate inflammation – visible glazing, redness,
oedema, and hypertrophy; bleeding on pressuring
or probing,
3. Severe inflammation – marked redness and
hypertrophy; tendency towards spontaneous
bleeding; ulceration.
The GI is the quotient of the sum of the values for all
gingival surfaces of the scored teeth and the number of
scored surfaces [36]. Gingivitis severity was scored as
follows: 0.1–1.0: mild inflammation; 1.1–2.0: moderate
inflammation, and 2.1–3.0: severe inflammation. Linear
gingival erythema, gingival overgrowth and pockets dee-
per than 4 mm (with the use of a calibrated periodontal
probe) were also reported.Microbiological examination
Oral swabs from the patients were cultured on Sabouraud
agar. After a 24–72 h incubation at 30°C, the following
items were assessed:
 Species identification with commercial tests ID 32
C, performed with automated ATB Expression [20],
 Assessment of enzyme activity: valine arylamidase
(E7), α-glucosidase (E16), β-N-acetyl-glucosamini-
dase (E18), performed with API 20 C AUX and API
ZYM tests [37,38].
The API-ZYM micro test using 20 micro-vials included
19 substrates to detect 19 hydrolytic enzymes. The first
micro-vial served as a negative control. The second con-
tained a substrate for alkaline phosphatase (E2). Micro-
vials 3–5 contained substrates for esterase (C4), esterase
lipase (C8), and lipase (C14). Micro-vials 6–10 contained
substrates for proteases. Finally, micro-vials 13–20 con-
tained substrates for glycosidases. The micro-vials were
filled with 65 μL of urine and incubated for 4–4.5 h at
37°C. Following the ncubation, , one drop of reagent
(ZYM A or ZYM B) was added to each micro-vial and
the intensity of the colour reaction was read after five
minutes, using special tables provided with the kit, with
scores from 0 to 5, where 0 corresponded to a negative
reaction (0 nmol), 1 to 5 nmol, 2 to 10 nmol, 3 to 20 nmol,
4 to 30 nmol, and 5 to a reaction with maximum intensity,
i.e. 40 nmol. Three Candida albicans isolates, out of eight
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enzymatic profiles.
Statistical analysis
For all variables, the mean values and standard devia-
tions (SD) or proportions were calculated. The t-test was
used to compare means in the examined groups, and the
chi-squared test was used to compare fractions. Correla-
tions between the selected variables were assessed using
the Kendall rank correlation coefficient (significance
level P < 0.05). The statistical analysis was performed
using the Statistica 10.0 software. Correlations between
the GI and selected properties were calculated jointly for
all groups to determine the ratio of ill and healthy sub-
jects in the population. Correlations were also calculated
separately for each group of ill children under study, to
check whether the correlation was similar to the one in
the entire population of healthy and ill subjects. It was
necessary to double-check them in order to avoid the
Simpson’s paradox, i.e. the effect of apparent correlations
resulting from important disparities among the assessed
groups. Moreover, a multiple regression analysis was
used to assess the simultaneous effect of many inde-
pendent variables on the GI. Partial standardised regres-
sion coefficients were presented.
Results
Medical status
The BMI in the NS group ranged between 14.36 and
41.0 kg/m2 and the BMI SDS was between −0.9 and 3.3
(mean BMI: 22.1 ± 6.06 kg/m2). In the diabetes group,
the BMI ranged between 14 and 32 kg/m2, and the BMI
SDS between −1.3 and 2.5 (mean BMI: 20.07 ± 3.52 kg/
m2). In the control group, the BMI ranged between 12.2
and 31 kg/m2 for the BMI, and between −2.2 and 2.3 for
the BMI SDS (mean BMI: 19.51 ± 4.12 kg/m2).
In the NS group, disease duration ranged between 0.5
and 15.67 years (mean duration: 5.06 ± 4.95 years). Thirty
patients with NS received immunosuppressive treatment,
including single drug immunosuppression in 14 patients
(with corticosteroids [CS]), immunosuppression with two
drugs in 11 patients (in seven patients, CS and cyclosporin
A [CsA], and in four patients, CS and azathioprine), and
immunosuppression with three drugs in five patients
(with CS, CsA and mycophenolate mofetil [MMF]). Cor-
ticosteroids, used by 29 patients (mean dose: 33.25 ±
19.9 mg/day, mean treatment duration: 3.99 ± 4.45 years),
and cyclosporin A was used in 10 patients (mean dose:
134.54 ± 48.0 mg/day, mean treatment duration 3.88 ±
2.95 years), were the most commonly administered drugs.
Proteinuria occurred in 23 patients with NS (71.87%), hy-
poalbuminemia in 23 patients (71.87%), decreased serum
total protein levels in 10 patients (31.25%), decreased
haemoglobin levels in four patients (12.5%), increasedhaematocrit in 16 patients (50.0%), hyperleukocytosis in
15 patients (46.87%), elevated cholesterol levels in 22 pa-
tients (68.75%), and elevated triglyceride levels in 14 pa-
tients (43.75%).
In patients with diabetes, the duration of the disease
ranged between 0.1 and 9.58 years (mean duration: 2.82 ±
2.5 years). Patients with diabetes received from 0.1 to 1.3
units of insulin/kg of body mass (mean 0.76 ± 0.29). Blood
sugar level ranged between 69 and 300 mg/dl. In 17 pa-
tients (48.57%), the Hb1c level was higher than 8% (un-
compensated diabetes) and in four patients (11.4%), it was
lower than 7%. Hypercholesterolemia occurred in seven
patients (20.0%) and higher blood triglyceride levels in five
patients (14.28%). Table 1 presents the mean values of the
evaluated biochemical parameters in patients with NS, as
well as the levels of glycated haemoglobin (HbA1c).
Oral cavity
Candida spp were frequently found in the oral cavity of
the controls (41.37% subjects), and less often in patients
with NS (34.37%, all under immunosuppressive treat-
ment) and those with diabetes (22.85%) (statistically
insignificant differences). Only Candida albicans was
isolated. Table 2 presents oral Candida prevalence in the
respective groups and the activity of the Candida en-
zymes obtained from the oral cavity, including valine
arylamidase (E7), alpha-glucosidase (E16), and N-acetyl-
beta-glucosaminidase (E18). A considerably higher level
of E16 activity was discovered only on comparing the
NS group to the control group (Table 2). Oral candidia-
sis was diagnosed in three patients with NS (9.37%) and
in four with diabetes (11.43%). Erythematous candidiasis,
pseudomembranous candidiasis with associated median
rhomboid glossitis, and angular cheilitis were resident in
patients with NS. Erythematous candidiasis (1), angular
cheilitis (3), and pseudomembranous candidiasis with as-
sociated median rhomboid glossitis were noted in pa-
tients with diabetes.
Gingivitis was more frequent in patients with diabetes
(80%) and with NS (62.5%) than in the controls (37.93%).
There was a statistically significant difference only be-
tween D1 and C (Table 3). No patient presented severe
gingivitis or periodontitis. Nine NS patients presented
periodontal pockets deeper than 4 mm in a single tooth,
caused by cyclosporine-associated gingival hyperplasia.
Moderate gingivitis was diagnosed significantly more often
in the NS group. Patients with both diabetes and NS
presented significantly higher GIs than did the controls.
Gingivitis was related to plaque presence in all the study
groups. ab. 3).
The Kendall rank correlation coefficient for NS and
controls, as well as for D1 and controls, also indicated a
correlation between GI and yeast enzyme activity (E7,
E16, and E18). In diabetes, the occurrence of only yeasts
Table 2 Candida spp. prevalence and activity of Candida enzymes isolated from the oral cavity in patients from the
control group (C), with Nephrotic syndrome (NS), and with type 1 diabetes (D1)
Group Candida spp. Activity of Candida enzymes isolated from oral cavity
Code E7 or E16 or E18 Code E7 Code E16 Code E18
1-5 5 1-5 5 1-5 5 1-5 5
n/% n
NS 11/34.37 11/34.37 8/25.00 11 1 9 5 10 6
D1 8/22.86 7/20.0 6/17.14 7 0 7 4 9 4
C 12/41.37 10/34.48 2/6.89 11 0 10 0 10 2
P-value - chi-squared test
NS vs C 0.573 0.993 0.057 0.773 0.337 0.592 0.026* 0.788 0.171
D1 vs C 0.111 0.192 0.217 0.112 1.000 0.192 0.060 0.445 0.536
*significantly different at P < 0.05.
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assessment of the respective groups indicated that inten-
sified gingivitis in the NS patients Nephrotic syndrome
was related only to a high E18 activity. Immunosuppres-
sive treatment, especially with more than one drug, dis-
ease duration, the BMI and BMI SDS, a higher blood
cholesterol level (mg/dL), and age had a crucial impact
on gingivitis severity in patients with NS. Additionally,
the duration of glucocorticoid treatment (significant
Kendall rank correlation coefficient: 0.258), and the dos-
age and duration of CsA treatment (significant Kendall
rank correlation coefficient: 0.461, 0.407) were also cor-
related with the GI. The assessment in D1 and controls
indicated a correlation between GI and age, as well as
disease duration and elevated blood glucose levels. The
correlation coefficient was statistically and significantly
negative for HbA1c <7%, and positive for HbA1c > 8%
(Table 4). A similar assessment only in the diabetes group
confirmed a negative correlation for HbA1c <7%. The re-
sults of the multiple regression analysis only confirmed
the correlation between GI and immunosuppressive treat-
ment and blood cholesterol levels in NS patients (partialTable 3 Oral hygiene (PLI) and gingivae condition (GI) in pati
diabetes (D1), and control (C)
Parametry NS
PL I mean ± SD 0.98 ± 0.61
GI 0.62 ± 0.69
GI ≥ 0.1 n/% 20/62.5
GI ≥ 1.1 10/31.25
Correlation between PL I and GI 0.482*
(P < 0.001)
*significantly different at P < 0.05; the t-test was used to compare means, and the cstandardised coefficients of multiple regression: 0.421 and
0.391). The coefficient of determination (R2) was between
0.309–0.662 (Table 4).
Since the analysis was performed only for the control
group, it indicated a correlation between the GI and the
BMI (statistically significant Kendall rank correlation coef-
ficient: 0.378). The analysis performed in all 96 patients
also confirmed a positive correlation between the GI and
the BMI (statistically significant Kendall rank correlation
coefficient: 0.204). However, correlations with the BMI
SDS were not statistically significant.
Discussion
There are many publications associating frequent gingi-
vitis and oral candidiasis with impaired immune defence
mechanisms, such as in organ recipients receiving im-
munosuppressive treatment, cancer patients receiving
cytotoxic treatment, patients with AIDS, or patients with
diabetes [1-12]. In the present study, candidiasis only oc-
curred in children with NS or diabetes. In those groups,
gingivitis was more frequent d and showed a more se-
vere course compared to that in the generally healthyents from groups: with nephrotic syndrome (NS), with
D1 C P-value
1.02 ± 0.51 0.53 ± 0.69 NS vs C 0.011*
D1 vs C 0.002*
0.47 ± 0.38 0.24 ± 0.42 NS vs C 0.014*
D1 vs C 0.026*
28/80.0 11/37.93 NS vs C 0.055
D1 vs C 0.001*
4/11.43 1/3.45 NS vs C 0.005*
D1 vs C 0.236
0.633* 0.670* -
(P < 0.001) (P < 0.001)
hi-squared test to compare fractions.
Table 4 Kendall Tau correlation coefficients (KTC) and partial standardized coefficient of multiple regression
(MR) between GI and Candida spp. occurrence, candidal enzymatic activity in oral cavity, and systemic factors
(immunosuppressive treatment, selected clinical and biochemical parameters) in the NS and C, NS, D1 and C, and
D1 groups
Parameters NS and C Only NS D1 and C Only D1
KTC MR KTC MR KTC MR KTC MR
Candida spp. occurrence 0.046 −0.042 0.082 0.080 0.180* −0.341 0.243* −0.708
Enzymatic activity of Candida spp.
isolated from the oral cavity
E7 0.222* 0.189 0.098 0.053 0.272* 0.211 0.463
code 5 −0.010 −0.343* −0.060 −0.344 - -
E16 0.215* 0.385 0.070 −0.220 0.316* 0.678 0.417* 0.424
code 5 0.094 −0.403 0.025 0.083 0.283* −0.173 0.377* −0.065
E18 0.259* −0.143 0.134 −0.377 0.260* −0.067 0.295* 0.648
code 5 0.273* 0.045 0.246* 0.583 0.229* 0.085 0.236* −0.329
Immunosuppressive treatment 0.205* −0.216 0.136 0.154 - - - -
>1 drug 0.359* 0.421* 0.388* 0.465 - - - -
Elevated cholesterol level 0.219* 0.391* 0.201 0.473* 0.038 - −0.137 -
Elevated triglyceride level 0.166 0.030 0.133 −0.067 0.115 - −0.061 -
HbA1c - - - - 0.300* 0.145 0.207 0.128
<7% - - - - −0.328* −0.282 −0.252* −0.218
>8% - - - - 0.255* −0.045 0.189 −0.016
Blood glucose level (elevated) - - - - 0.187* −0.098 0.026 −0.065
BMI 0.329* 0.289 0.302* −0.062 0.141 0.057 −0.105 0.168
BMI in SDS 0.240* −0.082 0.268* 0.191 0.030 −0.042 −0.067 −0.281
Disease duration 0.226* 0.136 0.256* 0.197 0.200* −0.063 −0.041 −0.033
Age 0.195* 0.033 0.151 0.003 0.201* 0.100 −0.052 0.000
Sex −0.006 0.110 0.149 0.340 −0.038 −0.056 0.131 0.006
R2 – coefficient of determination - 0.468 - 0.662 - 0.309 - 0.520
*statistically significant correlation (P < 0.05).
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gingivitis. The present study confirmed a correlation be-
tween GI, PLI, and the child and adolescent age.
Romero et al. also established that GI increased with
age in children, even though PLI decreased [39].Treat-
ment of gingivitis consisting in removal of the dental
plague and factors contributing to its retention may be
not successful in patients with systemic disease. Sys-
temic diseases are usually associated with diverse disor-
ders which may favourably affect the development of
gingivitis or increase its severity accompanied by diverse
disorders which may favourably affect the presence or/
development of gingivitis. Among them, there may be
nonmodifiable and modifiable factors whose influence
(=activity) may be nonmodifiable and modifiable fac-
tors, whose influence (activity) may be an may decrease
their effect and consequently achieve better more effect-
ive results.
The present study, assessing the impact of the respect-
ive factors, including the occurrence if Candida spp. in
the oral cavity, and the systemic disorders in diabetesand NS, selects factors associated with the disease or it’s
treatment influencing severity of gingivitis that may inten-
sify development. The study draws attention to consider-
ing antifungal treatment as element of gingivitis therapy.
It accentuates the significance of maintaining a proper
body weight. The assessment of the simultaneous impact
of factors (multiple regression) was not statistically sig-
nificant for most of them. It was caused of their mutual
correlations. However, the coefficients of determination
(R2) indicated a significant impact of the assessed fac-
tors on GI (Table 4).
Gingiva in children with NS has not been previously
assessed, however, the observation of patients with kid-
ney or liver transplants that are under immunosuppres-
sive treatments indicated a correlation between gingivitis
severity and GI [20,21]. Other authors concluded the
same in diabetes, independent of the definition of peri-
odontal disease [12,40-42]. Lalla et al., examining 83 pa-
tients with diabetes and 80 generally healthy children
and adolescents, confirmed that children with diabetes
presented significantly more dental plaque and a higher
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vs. 1.1, gingival index 1.2 vs. 1.1, respectively) [12]. Lalla
et al. used three definitions of periodontal disease: attach-
ment loss, gingival bleeding, or both. Their regression
analysis indicated that diabetes presented a statistically sig-
nificant correlation with periodontitis, even in the 6- to 11-
year-old group of patients with diabetes. However, they did
not find any correlation between the inflammation of peri-
odontal tissues and the degree of diabetes compensation
(mean HbA1C) and lipid profiles [12]. This is contrary to
the present study and to earlier evidence suggesting im-
proper management of diabetes and the associated meta-
bolic disorders predisposed to more severe periodontitis
[43]. Saes Busato et al. confirmed, in their study on young
patients with diabetes, with the results based on the
Community Periodontal Index (CPI), the negative im-
pact of improper diabetes management. Adolescents
with poor metabolic control presented a higher CPI
than did the group with good metabolic control (2.0 and
1.4, respectively) [42]. Lalla et al. noticed a correlation
between periodontitis in diabetes and BMI, which was also
confirmed by others authors that used adults in their stud-
ies [12,44,45]. The results of the present study also suggest
a correlation with gingivitis severity. However, it was only
evident for all of the patients together, independently of
their general health, and in controls and NS.
The correlation between GI and high cholesterol levels
in children with nephrotic syndrome is worth noting. A
higher level of cholesterol and triglycerides occurs in
nephrotic syndrome relapse and can be upheld for a
long period of time, even in remission [46]. Hyperlipid-
aemia in remission, and especially total cholesterol level
in the serum, is considered a predictor of idiopathic neph-
rotic syndrome relapse in children [47]. Patients with
diabetes also present higher cholesterol and triglyceride
(TRG) levels, even if the blood glucose level was well-
managed. Periodontitis-induced bacteraemia is also im-
plied increased serum pro-inflammatory cytokine levels,
leading to hyperlipidemia [11]. Although the present study
did not confirm correlations between the GI and lipid pro-
file disorders in diabetes, it is necessary to continue study-
ing both diseases in larger patient groups.
There many factors promoting periodontitis in diabetes
(such as alterations in host response, collagen metabolism,
vascularity, gingival crevicular fluid, and heredity patterns)
and in those receiving immunosuppressive treatment
(drugs, dosage, and treatment duration). However, the cor-
relation between gingivitis severity and yeast-like fungi in
the oral cavity was not assessed, even if fungal infections
occurred more often in these patients. In the present
study, yeast-like fungi less frequently colonised the oral
cavity of patients with nephrotic syndrome or diabetes,
compared to the generally healthy participants, but Can-
dida spp. more often led to candidiasis. There was nodifference between the enzymatic activity of the strains
isolated from the oral cavity in patients with NS and
diabetes and that of the controls. Plomer-Niezgoda et al.
showed different Candida enzymatic biotypes, accord-
ing to the Williamson classification, in patients under
immunosuppressive therapy (biotypes C and B) and
healthy subjects (biotypes A and B), but both groups
presented E7, E16, and E18 activity [48]. It is also inter-
esting to note that the present study established a
correlation between gingivitis and the local Candida en-
zyme oral activity, including valine arylamidase (E7),
alpha-glucosidase (E16), and N-acetyl-beta-glucosami-
nidase (E18). In Kurnatowska and Kurnatowski’s study,
40% of Candida albicans strains isolated in gingivitis
were biotype F, according to the Williamson classifica-
tion, i.e. characterised by esterase (E3), E7, naphthol-
AS-BI-phosphohydrolase (E12), and E16 activity, 15%
were biotype A (also presenting E18 activity), 5% bio-
type B (E3, E12, E16, and E18 activity), 5% biotype E
(E3, E7, and E12 activity), and 5% were biotype G (E3,
E12, and E16 activity). The remaining strains were clas-
sified as biotypes defined by those authors, including
15% as biotype N (E3 and E18 activity), 5% as biotype I
(E18 activity only), and 5% as biotype K (E3, E7, and
E16 activity) [49]. These results do not only confirm a
correlation between gingivitis and E7, E16, and E18 ac-
tivity, but also indicate that the N-acetyl-beta-glucosa-
minidase activity is related to inflammation severity.
Considering the role of E18 in the formation of invasive
germ tubes, these results may confirm the etiopathoge-
netic role of Candida in the development of gingivitis.
Conclusions
The main cause of gingivitis is poor oral hygiene. There is
most likely a correlation between gingivitis severity and
age, BMI and lipid disorders. Candida spp., residing in the
oral cavity of patients with uncompensated diabetes or
those receiving multi-drug immunosuppressive treatment,
may potentiate the severity of plaque-related gingivitis.
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